Lilly gets FDA EUA for bebtelovimab to treat mild-to-moderate Covid-19
According to pseudovirus and authentic virus data, bebtelovimab has shown neutralisation activity against widely circulating variant of concern,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
14 Feb 22
According to pseudovirus and authentic virus data, bebtelovimab has shown neutralisation activity against widely circulating variant of concern,…
11 Feb 22
The US drugmaker has used several insights from the CytoReason’ platform, in several of its R&D programmes across…
11 Feb 22
The investigational Covid-19 drug, bebtelovimab, has shown to maintain binding and neutralising activity across currently known and reported…
10 Feb 22
We focus on the importance of collaboration, outsourcing relationships and avoiding bottlenecks to find out what makes a…
10 Feb 22
The investment round, jointly led by SoftBank Vision Fund 2 and RA Capital Management, will advance the company’s…
09 Feb 22
Juvéderm Volbella XC is said to be the first and only dermal filler to receive FDA approval for…
08 Feb 22
Biogen will obtain exclusive global regulatory, manufacturing, and commercial rights to Xcimzane, along with the marketing authorisation
07 Feb 22
A look at how Covid-19 has led to more complexity in the sourcing of ancillary supplies and what…
07 Feb 22
The FDA approval of Enjaymo is based on positive results from the Phase 3 CARDINAL trial, a 26-week…
07 Feb 22
With the DCGI authorisation, Sputnik Light will be included in India's national vaccine portfolio, joining Sputnik V, which…